(Press-News.org)
(MEMPHIS, Tenn. – March 12, 2026) – St. Jude Children’s Research Hospital today announced the appointment of Carsten Bönnemann, MD, as a faculty member to lead and chair the hospital’s newly created Department of Genomic and Translational Neuroscience.
Bönnemann, who specializes in pediatric neuromuscular and neurogenetic disorders, comes to St. Jude from the National Institutes of Health, where he served as a physician-researcher and chief of the Neuromuscular and Neurogenetic Disorders of Childhood Section. While at the NIH, Bönnemann’s pioneering research led to key discoveries, including identifying a genetic cause of juvenile amyotrophic lateral sclerosis, advancing understanding of the genetics of neuromuscular disorders and the first in-human intrathecal application of AAV gene therapy for giant axonal neuropathy.
“Joining St. Jude is an extraordinary opportunity to accelerate discoveries for children with catastrophic neurological disorders. The mission of this new department is to understand the unique genetic and molecular roots of these devastating disorders and conceptualize genetic precision therapies based on this knowledge,” Bönnemann said. “At St. Jude, we have the ability to accelerate research and therapeutic discovery using cutting-edge science. By collaborating with colleagues across the institution, we will be able to push the boundaries of research, help discover the root causes of these disorders, and help configure new and unique therapeutics for patients where few options exist.”
The Department of Genomic and Translational Neuroscience at St. Jude was formed as a natural extension of the institution’s commitment to children living with catastrophic neurological disorders. The aim is to change the treatment landscape and improve the quality of life through preclinical and clinical research.
The department advances the Pediatric Translational Neuroscience Initiative and houses both the Center for Pediatric Neurological Disease Research (CPNDR), which drives basic research into complex pediatric neurological conditions, and the Center for Experimental Neurotherapeutics (CENT), which accelerates clinical development of promising treatments and will add new initiatives around genomic diagnosis and precision targeting of genetic therapies. Faculty members for the Department of Genomic and Translational Neuroscience include Bönnemann; Fernando Alsina, PhD; Xiaoyu Chen, PhD; Richard Finkel, MD; Andrea Gropman, MD; Dolores Irala, PhD; Peter McKinnon, PhD; and Heather Mefford, MD, PhD.
“Catastrophic neurological diseases are rare, aggressive and biologically complex conditions that demand deep scientific focus and long-term commitment to understand the disease itself and develop effective therapies,” said J. Paul Taylor, MD, PhD, executive vice president, scientific director and Pediatric Translational Neuroscience Initiative director. “What makes St. Jude unique is the integration of different disciplines — laboratory discovery, therapy development, manufacturing and clinical delivery — all happening under one roof. The addition of Dr. Bönnemann as department chair will continue to push St. Jude forward in the creation of leading-edge, personalized therapies that target the root cause of these rare and ultra-rare conditions, offering hope where few options currently exist.”
Bönnemann completed medical school at the Albert-Ludwigs University in Freiburg, Germany, and completed his residency in pediatric neurology at Massachusetts General Hospital and Harvard Medical School, and a fellowship in neuromuscular neurology at Boston Children’s Hospital. Bönnemann also completed postdoctoral research studying the molecular genetics of muscular dystrophy at Boston Children’s. He has received numerous awards, including the MDA Legacy Award for Achievement in Clinical Research and the George Jacoby Award from the American Neurological Association.
###
St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is leading the way the world understands, treats, and cures childhood catastrophic diseases. From cancer to life-threatening blood disorders, neurological conditions, and infectious diseases, St. Jude is dedicated to advancing cures and means of prevention through groundbreaking research and compassionate care. Through global collaborations and innovative science, St. Jude is working to ensure that every child, everywhere, has the best chance at a healthy future. To learn more, visit stjude.org, read St. Jude Progress, a digital magazine, and follow St. Jude on social media @stjuderesearch.
St. Jude Media Relations Contacts
Chelsea Bryant
Desk: (901) 595-0564
Cell: (256) 244-2048
chelsea.bryant@stjude.org
media@stjude.org
END
To understand how professional networks contribute to persistent gender disparities in corporate leadership, researchers analyzed data from more than 19,000 corporate employees over 20 years. Publishing March 12 in the Cell Press journal Patterns, their results show that educational, employment, and social networks matter for both men and women, but women rely on more complex social networks to reach director-level positions than men. Women with professional ...
Mass General Brigham study results signal a call to do further research into the connection between vitamin D supplementation and long COVID
In a large, randomized trial, researchers at Mass General Brigham have found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes. Results of the study are published in The Journal of Nutrition.
“There’s been tremendous interest in whether vitamin D supplements can be of benefit in COVID, and this is one of the largest and most rigorous randomized trials on the subject,” said senior author JoAnn Manson, MD, DrPH, ...
A new study led by UCLA researchers suggests that a personalized counseling program can significantly help women who have survived cervical precancer or cervical cancer to quit smoking — and does so at a cost that researchers say represents good value for healthcare systems.
The findings, published in JAMA Network Open, show that the specialized program, called Motivation and Problem-Solving (MAPS), which combines standard nicotine replacement therapy with up to six individualized counseling sessions over a year, helped twice as many women quit smoking compared to women who had standard smoking cessation support.
“Smoking is a major risk factor for cancer recurrence and ...
About The Study: In this cohort study, adverse childhood experience (ACE) exposure was associated with an increased risk of treatment-resistant depression even after accounting for unmeasured familial confounding. The findings highlight the importance of preventing ACEs and incorporating ACE history into clinical assessment to identify individuals with major depressive disorder who may be at elevated risk for treatment resistance.
Corresponding Author: To contact the corresponding author, Ying Xiong, PhD, MMedSc, email ying.xiong@ki.se.
To access the embargoed study: Visit our For The Media website at this ...
About The Study: This study estimated the increase in 12-month psilocybin use in Oregon and Colorado associated with decriminalization.
Corresponding Author: To contact the corresponding author, Joshua C. Black, PhD, email joshua.black@rmpds.org.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.1952)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, ...
A new, national analysis published in the Aesthetic Surgery Journal suggests the future growth of aesthetic surgery may lie far from traditional luxury markets. UC Davis Health researchers found that Southern, Midwestern and rural regions of the United States are growing as high-demand areas, despite limited access to board-certified plastic surgeons.
The study, conducted by researchers at UC Davis Medical Center, analyzed Google search behavior alongside workforce data across 210 U.S. Designated Market Areas. Researchers found that consumer demand is rising nationwide but remains unevenly matched with surgeon distribution. This imbalance has revealed multiple “plastic surgery deserts” ...
A University of Virginia School of Medicine researcher has received $3.4 million from the National Institutes of Health to increase the availability of weight-management programs that offer beneficial personalized feedback.
Rebecca Krukowski, PhD, and her colleagues are aiming to support people who track or “self-monitor” their diet, exercise and weight in weight-management programs. The researchers will create a semi-automated feedback system to find the “sweet spot” of combining human expertise and support with automated feedback to help participants stay on ...
(WASHINGTON — Mar. 12, 2026) — Hematology-oncology trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in grit and resilience between the two groups. The data were published in the American Society of Hematology’s journal, Blood Advances.
“This is the first and only data on burnout, grit, ...
The Amazon rainforest is famous for storing massive amounts of carbon in its trees and soils, helping regulate the global climate. Yet a paper published today in New Phytologist shows that one of South America’s largest carbon-storing ecosystems exists in an often-overlooked grassy savanna: the Cerrado in Brazil.
The study was led by Larissa Verona, a technician working with senior scientist Amy Zanne at Cary Institute of Ecosystem Studies and a former graduate student at Universidade Estadual de Campinas in Brazil, where she carried out the work. The study is the first in-depth assessment of carbon stocks in the Cerrado’s groundwater-fed wetlands, known ...
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms, characterized by muscle wasting, paralysis, dementia, and other serious impairments. There are currently no effective treatments. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered ...
